Topical administration of oleandrin could protect against gentamicin ototoxicity via inhibition of activator protein-1 and c-Jun N-terminal kinase.
Emanuele
Enzo
E
Olivieri
Valentina
V
Aldeghi
Alessia
A
Minoretti
Piercarlo
P
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000633:toxicity; D002298:Cardenolides / Q000008:administration & dosage* / Q000627:therapeutic use*; D004423:Ear; D005839:Gentamicins / Q000633:toxicity*; D006198:Hair Cells, Auditory / Q000187:drug effects; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D002298:Cardenolides; D005839:Gentamicins; D018808:Transcription Factor AP-1; D048031:JNK Mitogen-Activated Protein Kinases; C021065:oleandrin